Erin Schenk, MD, PhD, assistant professor of medicine, Division of Medical Oncology, University of Colorado School of Medicine, medical oncologist, University of Colorado Medicine, discusses the importance of investigating novel targets and pathways in lung cancer.

The list of novel targets being evaluated in lung cancer is rapidly expanding, Schenk says. Moreover, as the field develops a greater understanding of disease biology and resistance mechanisms in lung cancer, novel pathways become relevant options for targeted therapy. Moreover, emerging novel targets inform clinical trial designs, Schenk adds.

Currently, emerging targets, such as TROP2, KEAP1, HER3, IL-2, SHP2, and TGF-β, have informed potentially novel options for treating patients with lung cancer or overcoming resistance to some of the therapies that are currently available, Schenk concludes. 

Videos

Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.  



Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer 

Erin Schenk, MD, PhD, assistant professor of medicine and medical oncology, Division of Medical Oncology, University of Colorado Cancer Center, discusses the rapidly evolving treatment landscape in lung cancer.

The incorporation of pembrolizumab (Keytruda) in the first-line setting ​of non–small cell lung cancer, in addition to a multitude of immuno-oncology agents ​in extensive-stage small cell lung cancer, continues to evolve the lung cancer space, says Schenk.

 have provided the field with a better understanding of how cancer interacts with the immune system and shed light on the importance of clinical trials, Schenk adds.

​Moreover, all patients with lung cancer should be consider​ed for clinical trials evaluating biospecimens or new immuno-oncology agents, Schenk concludes.

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

Erin Schenk, MD, PhD

Articles

Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer

Dr. Schenk on the Evolving Treatment Landscape in Lung Cancer